Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.

Medical oncology (Northwood, London, England) - 1 Dec 2010

Eissa Sanaa, Zohny Samir F, Zekri Abdel-Rahman N, El-Zayat Tarek Mostafa, Maher Amany M

Abstract excerpt

Development of new methods for bladder cancer detection is required because cystoscopy is invasive, and voided urine cytology (VUC) has low sensitivity. The aim of this study was to evaluate the diagnostic performance of urinary fibronectin and mutant p53 in comparison with VUC in the detection of bladder cancer. This study included 100 patients diagnosed with bladder cancer, 93 patients with benign urological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Fibronectins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoenzyme Techniques

Share to Lymphatic Metastasis

Share to ROC Curve

Share to Schistosoma mansoni

Share to Schistosomiasis

Share to Urinary Bladder

Source

Identifiers

PMID: 20012564
DOI: 10.1007/s12032-009-9375-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.PMID 20012564Read ↗

TP53 Mutation for Prediction of Tumor Recurrence and Metastasis in Bladder Cancer PatientsSemantic proximity Read ↗

Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence.Semantic proximity Read ↗

Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and SurveillanceSemantic proximity Read ↗

Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?Semantic proximity Read ↗

Molecular classification and diagnostics of upper urinary tract urothelial carcinoma.Semantic proximity Read ↗

Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkersSemantic proximity Read ↗

Detection of bladder cancer using urinary cell‐free DNA and cellular DNASemantic proximity Read ↗

A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.Semantic proximity Read ↗

Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter StudySemantic proximity Read ↗

Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise?Semantic proximity Read ↗

Molecular markers for detection, surveillance and prognostication of bladder cancer.Semantic proximity Read ↗

Molecular pathogenesis and diagnostics of bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.